Journal of Leukocyte Biology
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


Originally published online as doi:10.1189/jlb.0506322 on October 11, 2006

Published online before print October 11, 2006
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
jlb.0506322v1
81/1/250    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Baroni, E.
Right arrow Articles by D’Ambrosio, D.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Baroni, E.
Right arrow Articles by D’Ambrosio, D.
(Journal of Leukocyte Biology. 2007;81:250-262.)
© 2007 by Society for Leukocyte Biology

VDR-dependent regulation of mast cell maturation mediated by 1,25-dihydroxyvitamin D3

Enrico Baroni*,1, Mauro Biffi*, Fabio Benigni*, Antonia Monno*, Donatella Carlucci*, Geert Carmeliet{dagger}, Roger Bouillon{dagger} and Daniele D’Ambrosio*

* Bioxell SpA, Milano, Italy; and
{dagger} Laboratory of Experimental Medicine and Endocrinology, K. Universiteit of Leuven, Leuven, Belgium

1Correspondence: BioXell S.P.A., Via Olgettina, 58, 20132 Milano, Italy. E-mail: enrico.baroni{at}bioxell.com


    ABSTRACT
 TOP
 ABSTRACT
 INTRODUCTION
 MATERIALS AND METHODS
 RESULTS
 DISCUSSION
 REFERENCES
 
1,25-Dihydroxyvitamin D3 [1,25(OH)2D3] is a secosteroid hormone that regulates bone metabolism, controls calcium homeostasis, and possesses immunomodulatory properties. We show here that 1,25(OH)2D3 contributes to the regulation of development and function of mast cells, which play a critical role in several inflammatory disorders. 1,25(OH)2D3 promotes apoptosis and inhibits maturation of mouse bone marrow-derived mast cell precursors. Dose-dependent inhibition of mast cell differentiation by 1,25(OH)2D3 is observed at discrete, intermediate stages of mast cell development, identified by expression of c-kit, Fc{epsilon}RI, and IL-3 receptor-{alpha} chain, and depends on the expression of the vitamin D receptor (VDR). It is important that mast cell progenitors obtained from VDR-ablated mice undergo an accelerated maturation in vitro and give rise to more responsive mast cells than wild-type. Furthermore, histological analysis of mast cell density in peripheral tissues reveals a moderate increase in the number of mast cells in the skin of VDR-deficient mice compared with wild-type animals. These data support the hypothesis of a physiological role of 1,25(OH)2D3 in mast cell development and suggest novel, therapeutic uses of 1,25(OH)2D3 analogs.

Key Words: apoptosis • maturation • bone marrow • cell surface molecules


    INTRODUCTION
 TOP
 ABSTRACT
 INTRODUCTION
 MATERIALS AND METHODS
 RESULTS
 DISCUSSION
 REFERENCES
 
1,25-Dihydroxyvitamin D3 [1,25(OH)2D3], the active metabolite of vitamin D3, is a secosteroid hormone, which exerts its actions through the binding to a nuclear hormone receptor, vitamin D receptor (VDR). 1,25(OH)2D3 was originally identified as a key regulator of bone metabolism and calcium homeostasis, but its biological actions were subsequently shown to include regulation of immunity, angiogenesis and growth, differentiation, and apoptosis of many cell types, including malignant cells [1 2 3 ]. Much interest has been focused in recent years on the protolerogenic immunoregulatory properties of 1,25(OH)2D3, raising the possibility to use VDR ligands as potential therapeutic agents to treat a series of important immunomediated disorders [4 ].

The immunoregulatory properties of VDR ligands have been studied in different models of autoimmune diseases and allograft rejection. However, the cellular and molecular targets for anti-inflammatory activity of 1,25(OH)2D3 appear to be complex and remain not fully elucidated [4 , 5 ].

Mast cells (MCs), which act as potent triggers and amplifiers of inflammatory and allergic responses, are one of the main effector cells of the Th2 response. Cross-linking of the high-affinity Fc{epsilon}RI by multivalent antigens bound to IgE antibodies provides the main immunological stimulus for MC activation, operating in type I hypersensitivity and anaphylactic reactions [6 7 8 ]. MCs are also triggered by a variety of immunological and nonimmunological stimuli, such as complement components, cytokines, bacterial and viral constituents, kinins, and neuropeptides [9 , 10 ]. The activation of MCs not only causes the release of preformed, granule-associated mediators but also initiates the de novo synthesis of lipid-derived substances and cytokines [11 ].

MCs are the progenies of hematopoietic stem cells. Progenitor cells leave the bone marrow and after entering the circulation as undifferentiated cells, seed peripheral tissues such as lung, bowel, and skin, where they finally differentiate into mature MCs in response to yet poorly defined signals. Mouse MCs (mMCs) can be generated in large amounts from bone marrow cells cultured in the presence of IL-3 [12 ]. The c-kit ligand stem cell factor (SCF) also plays a critical role in MC survival, proliferation, activation, and mediator content release [13 14 15 ].

MCs, like many immune cell types, express VDR and respond to 1,25(OH)2D3 [16 ]. Previous studies exploring the effects of 1,25(OH)2D3 on activation of mature MCs reported contrasting evidence, and 1,25(OH)2D3 was reported as an inhibitor of calcium ionophore-induced histamine release by peritoneal MCs [17 ] and as an enhancer of IgE-mediated C57 MC line degranulation [18 ]. However, the biological effects of 1,25(OH)2D3 on MCs remain largely unexplored. In this paper, we describe extensive studies aimed at characterizing the biological activities of 1,25(OH)2D3 on MC proliferation, survival, differentiation, and function. Our results suggest that 1,25(OH)2D3, although only partially affecting release of inflammatory mediators upon Fc{epsilon}RI cross-linking, inhibits MC differentiation by promoting apoptosis of MC precursors. Furthermore, the lack of VDR signaling in VDR-deficient bone marrow cells leads to an accelerated differentiation into mature MCs in vitro. Moreover, histological analysis of MC density in different tissues reveals a moderate increase in the number of MCs in the skin of VDR-deficient mice compared with wild-type animals, which does not relate to changes in levels of serum calcium. These observations, beside demonstrating a negative effect of 1,25(OH)2D3 on MC precursors, support a role for VDR in MC development under physiological conditions.


    MATERIALS AND METHODS
 TOP
 ABSTRACT
 INTRODUCTION
 MATERIALS AND METHODS
 RESULTS
 DISCUSSION
 REFERENCES
 
1,25(OH)2D3
1,25(OH)2D3 was provided by Dr. Milan Uskokovic (BioXell Inc., Nutley, NJ). The compound was reconstituted with 100% ethanol (EtOH) and stored at –80°C in an oxygen-free atmosphere in the dark. In all experiments, equal amounts of 100% EtOH (vehicle) were added to control cultures.

Animals
BALB/c mice (8- to 12-weeks old, female, 18–22 g), purchased from Charles River Laboratories (Calco, Lecco, Italy), were used in all experiments unless otherwise specified. Swiss mice-derived VDR-knockout (Leuven VDR KO) mice and relative control littermates [19 ] were used in the analysis after genotyping by PCR analysis of genomic DNA extracted from tail biopsies. They were fed on a normal diet or on a calcium-enriched diet to prevent hypocalcemia as a result of the absence of VDR activity. All mice were bred in the animal housing facilities of K. Universiteit Leuven (Proefdierencentrum Leuven, Belgium). The Institutional Review Board has approved all animal studies.

Isolation and culture of mouse bone marrow cells
Femurs from BALB/c or Leuven female mice were cleaned and cut at their edge. Bone cavity was washed three times with RPMI 1640 supplemented with 15% FCS (HyClone, Logan, UT), glutamax (Gibco-BRL, UK), pen/strep (Gibco-BRL), and 50 µM ß-ME. Cell suspension was filtered through 70 µm pore membrane (352350, BD Falcon) and then, washed once with complete medium. Prior to culture at 37°C with 5% CO2, 0.5% of an IL-3-containing supernatant, prepared from the transgenic mouse cell line topoisomerase 3-IL-3, was added to the cell suspension. When required, recombinant (r)SCF (455-MC/CF, R&D Systems, Minneapolis, MN) was added at the concentration of 100 ng/ml. Cells were kept at a concentration ranging from 5 x 105 to 1 x 106 cells/ml, changing medium and flask every 4–7 days. In some cases, cultures were enriched in hematopoietic progenitors using a lineage cell depletion kit (130-090-858, Miltenyi Biotec, Auburn, CA).

RT-PCR
Total RNA was extracted from cells using a commercial kit (74104, Qiagen RNeasy mini kit, Qiagen, Valencia, CA), followed by treatment with DNase I. RNA concentrations were finally quantified with a Nanodrop® ND-1000 spectrophotometer.

RT was performed with RT reagent (N-8080234, Applied Biosystems, Foster City, CA) with random hexamers (according to the manufacturer’s instructions). Real-Time PCR was performed in 96-well optical reaction plates (Applied Biosystems). The amplification master mix was prepared according to the following protocol (volumes refer to a single well with a final volume of 40 µl/well): 2x TaqMan® Universal PCR Master mix (4304437, Applied Biosystems), 20 µl; 20x assay target gene, 2 µl; H2O, 8 µl; cDNA, 10 µl. Reactions were run on a SDS 7000 (Applied Biosystems) instruments with the following amplification program: 2 min at 50°C; 10 min at 95°C; 15 s at 95°C; and 1 min at 60°C for 40 cycles. Cycle threshold (Ct) values were then exported, and relative quantitations were performed using the {Delta}Ct method. All primers/probe assays used were purchased from Applied Biosystems and carried the FAM reporter. Assays used include hypoxanthine guanine phosphoribosyl transferase (HPRT; Mm00446968_m1), VDR (Mm00437297_m1), and Cyp24 (assay-by-design, mCYP24-EX56, forward primer: 5'-ACAGCGAGCTGAACAAATGGT-3', reverse primer: 5'-AGGAGCCCGAATCTCTTCTCATAT-3', reporter sequence: 5'-CAAGGCAGATGCTTTCA-3').

Cell proliferation assay
Freshly isolated bone marrow cells were cultured in Costar 96-well plates, round bottom (1.5x104 cells/well), with or without murine rIL-3 (0.5%), in the presence or absence of increasing concentrations of 1,25(OH)2D3 (1, 10, 100, 1000 nM), with or without 100 ng/ml SCF. After 8 days of culture, plates were centrifuged and after removal of the supernatant, frozen at –80°C to lyse the cells. CyQUANT cell proliferation assay kit (Molecular Probes, Junction City, OR) was used for measuring cell proliferation, according to the manufacturer’s instructions.

FACS analysis
A Becton Dickinson (San Jose, CA) LSR instrument was used for all FACS analyses. Cell sorting was performed at the core facility of San Raffaele Hospital (HSR, Milan, Italy) using a Becton Dickinson FACSVantage SE with FACSDiva option.

Stainings with annexin V and propidium iodide (PI) were performed with the annexin V apoptosis detection kit I (BD PharMingen, San Jose, CA, Cat. No. 556547) to determine the percentage of apoptotic and dead cells in the cultures. Only cells appearing as single-positive staining for annnexin V were considered apoptotic, and those appearing as double-positive staining for annexin V and PI were gated as dead cells.

The following antibodies were used to check cell differentiation: PE-anti c-kit (PE anti-CD117, 553869, BD PharMingen), FITC anti-IgE (553415, BD PharMingen), purified IgE (IgE anti-TNP, 557079, BD PharMingen), PE anti-IL-3 receptor-{alpha} chain (IL-3R{alpha}; CBL 1362P, Chemicon, El Segundo, CA), FITC anti-c-kit (553354, BD PharMingen).

Cell stimulations and assays for inflammatory mediators release
Mature bone marrow-derived MCs (BMMCs) were stimulated by plating onto 96-well plates previously coated with purified anti-TNP IgE antibodies (557079, BD PharMingen). After 30 min of stimulation, ß-hexosaminidase levels were measured in the culture supernatants and in control cell lysates by hydrolysis of p-nitrophenyl-N-acetyl-ß-D-glucopyranoside (Sigma-Aldrich, St. Louis, MO) in 0.1 M sodium citrate buffer (pH 4.5) for 40 min at 37°C. The percentage of ß-hexosaminidase release was calculated as described previously [20 ].

To determine levels of other inflammatory mediators, supernatants were collected after 24 h of stimulation with plate-bound IgE antibodies and stored at –80°C until quantitation. Upon analysis, samples were thawed and assayed for the content of IL-6 and IL-13 (R&D Systems mini kit), leukotriene C4 (LTC-4; 520211, Cayman LTC-4 enzyme immunoassay kit, Cayman Chemicals, Ann Arbor, MI), and mMC-derived protease 1 (mMCP-1; MMCP-1 ELISA kit, Moredun Scientific Ltd., UK).

Assays were performed on at least three replicates and repeated at least three times.

Cytospin preparations
Cells were centrifuged (Shandon Cytospin 4) at 1500 rpm for 5 min, using Shandon Single Cytofunnel (5991040, Shandon, Thermo Electron Corp., Waltham, MA) sample chambers on Menzel-Glaser (SuperFrost Plus, J1800AMNZ) glass slides, which were then stained with toluidine blue (Bio-Optica, Ireland) or with anti-VDR antibody (MA1-710, Affinity BioReagents, Golden, CO) for evaluation of cell phenotype by microscopic examination. Images were taken with a Leica DC200 camera mounted on a Leica HC microscope.

Histological preparations and samples evaluation
Upon sacrifice, skin samples were embedded in OCT (BDH, Milan, Italy) and frozen in liquid nitrogen-cooled isopentane. Frozen tissues were then cut (5 µm thickness) and stained with toluidine blue (Bio-Optica) for MC density evaluation. Number of cells over 10 high-powered fields (HPF; 1 HPF=2.3 mm2) was determined. Results are reported as number of MCs per mm2 dermis.

Measurement of serum calcium levels
Upon sacrifice, blood samples were collected from wild-type and VDR-KO animals. Briefly, sera were prepared by incubation at 37°C followed by centrifugation at 4°C and removal of precipitates. Calcemia was evaluated by using a commercial colorimetric kit (Calcium Dry-Fast, Sentinel, Milan, Italy).

Statistical analyses
Student’s t-test analysis was performed when comparing two groups, and one-way ANOVA followed by Dunnet’s post-hoc analysis was performed to compare more than two groups.


    RESULTS
 TOP
 ABSTRACT
 INTRODUCTION
 MATERIALS AND METHODS
 RESULTS
 DISCUSSION
 REFERENCES
 
Expression of VDR and responsiveness to 1,25(OH)2D3 in mature BMMCs
Isolated mouse bone marrow cells were cultured in IL-3-containing medium for a period of several weeks. Acquisition of MC phenotype was monitored by FACS analysis of c-kit and Fc{epsilon}RI surface expression, which can be detected easily by staining with IgE antibodies followed by staining with anti-IgE antibodies [21 ]. Efficiency and specificity of the staining method were confirmed by parallel analysis of Fc{epsilon}RI mRNA expression (data not shown). After 5 weeks in culture, we obtained a population, mainly consisting of mature BMMCs, as defined by their double-positive staining for c-kit and Fc{epsilon}RI receptors (data not shown) and by morphological analysis (Fig. 1A ). Furthermore, staining the same cells with anti-VDR antibody revealed expression of the VDR, mostly localized in the nucleus (Fig. 1B) .


Figure 1
View larger version (19K):
[in this window]
[in a new window]

 
Figure 1. VDR expression and responsiveness to 1,25(OH)2D3 of mouse BMMCs. (A) Toluidine blue staining of mature BMMCs. (B) Staining of mature BMMCs with anti-VDR antibody. (C) Quantitative RT-PCR analysis of mature BMMCs. Cells were cultured for 24 h in the presence or absence of 100 nM 1,25(OH)2D3 before being collected and analyzed for gene expression. The y-axis reports the values of expression relative to the housekeeping gene (HPRT). P < 0.05 for all comparisons.

 
To determine the responsiveness of mature BMMCs to 1,25(OH)2D3, we incubated cells in the presence or absence of 1,25(OH)2D3 and purified RNA to analyze expression of VDR and Cyp24, a mitochondrial enzyme involved in the metabolism of 1,25(OH)2D3, which is up-regulated in response to 1,25(OH)2D3 [22 ]. Real-time PCR analysis confirmed expression of VDR in BMMCs and revealed a strong induction of VDR and Cyp24 gene expression in the presence of 1,25(OH)2D3 (Fig. 1C) .

1,25(OH)2D3 reduces release of inflammatory mediators upon activation of mature BMMCs
The potential effects of 1,25(OH)2D3 on activation of mature MCs were then investigated. It is well known that large amounts of inflammatory mediator release, including ß-hexosaminidase and LTC-4, and expression of several inflammatory genes are induced following Fc{epsilon}RI cross-linking on fully mature BMMCs [23 24 25 ].

To evaluate if 1,25(OH)2D3 could affect degranulation of mature BMMC, we incubated fully mature MCs with 1,25(OH)2D3 for 24 or 48 h, before plating them into 96-well plates previously coated with IgE antibodies. After 30 min, supernatants were collected and assayed for ß-hexosaminidase activity. Although 24 h preincubation with 1 µM 1,25(OH)2D3 did not affect ß-hexosaminidase release in the assay buffer, 48 h treatment significantly reduced exocytosis induced by the two highest concentrations of IgE antibodies (Fig. 2A ). Release of IL-13, mMCP-1 and LTC-4 was also assayed, after 24 h stimulation following 96 h preincubation with 1 µM 1,25(OH)2D3. As shown in Figure 2B , treatment with 1 µM 1,25(OH)2D3 moderately, but significantly, reduced release of mMCP-1 and LTC-4, and release of the cytokine IL-13 was unchanged. Viability of mature BMMCs was not affected by 1,25(OH)2D3 treatment, neither in these assays nor after longer incubation times (data not shown).


Figure 2
View larger version (21K):
[in this window]
[in a new window]

 
Figure 2. 1,25(OH)2D3 negatively regulates release of inflammatory mediators by BMMCs after cross-linking of Fc{epsilon}RI. BMMCs obtained from wild-type or VDR-KO mice were incubated in the presence or absence of 1,25(OH)2D3 and stimulated by plating onto 96-well plates previously coated with purified IgE antibodies. (A) Following 24 or 48 h of exposure to 1 µM 1,25(OH)2D3 and after 30 min of stimulation, supernatants were collected and assayed for the levels of ß-hexosaminidase; results are expressed as percent of total cell content of ß-hexosaminidase, as revealed by assay of equal number of cells lysed with Triton X-100. (B) Following 96 h of exposure to 1 µM 1,25(OH)2D3 and after 24 h of stimulation, supernatants were assayed for the content of IL-13, mMCP-1, and LTC-4. All experiment were repeated at least three times. *, P < 0.05; **, P < 0.01. ns, Not significant.

 
Additional experiments conducted with lower doses of 1,25(OH)2D3 (100 nM) revealed that the inhibitory effects were only observed at high concentrations of the secosteroid hormone (data not shown). Given that the observed effects were partial and were only achieved at high concentrations of 1,25(OH)2D3, the biological relevance of this observation might be called into question.

Expression of VDR and responsiveness to 1,25(OH)2D3 in BMMCs
We then asked if 1,25(OH)2D3 could exert stronger effects on BMMC precursor proliferation and differentiation rather than on activation of mature MCs. First, to determine the responsiveness of mouse bone marrow cells to 1,25(OH)2D3, we incubated freshly isolated bone marrow cells in the presence or absence of 1,25(OH)2D3 and purified RNA to analyze expression of VDR and Cyp24. Real-time PCR analysis confirmed expression of VDR in bone marrow cells and revealed a strong induction of Cyp24 gene expression in the presence of 1,25(OH)2D3 (Fig. 3A ). It is interesting that IL-3 culture of bone marrow cells resulted in induction of VDR expression (Fig. 3A , left panel).


Figure 3
View larger version (21K):
[in this window]
[in a new window]

 
Figure 3. VDR expression and responsiveness to 1,25(OH)2D3 of mouse BMMCs. (A) Quantitative RT-PCR analysis of freshly isolated or cultured BMMC. Cells were cultured for 2 days in the presence or absence of 100 nM 1,25(OH)2D3, before being collected and analyzed for gene expression. P < 0.05 for all comparisons. (B) Cell proliferation assay. Freshly isolated bone marrow cells were cultured in IL-3-containing medium, in the presence or absence of 100 nM 1,25(OH)2D3, with or without 100 ng/ml SCF. After 8 days of culture, cell pellets were frozen and analyzed by a commercial cell proliferation assay, which has been performed more than three times. ***, P < 0.001, versus [IL-3+SCF; no 1,25(OH)2D3]; °°°, P < 0.001, versus [IL-3; no 1,25(OH)2D3].

 
Dose-dependent inhibition of IL-3-induced bone marrow cell proliferation by 1,25(OH)2D3
Next, we asked if 1,25(OH)2D3 treatment might influence in vitro MC differentiation from bone marrow precursors. To assess a possible effect of 1,25(OH)2D3 on bone marrow cell proliferation in the presence of IL-3, we cultured freshly isolated bone marrow cells in medium containing increasing concentrations of 1,25(OH)2D3 in the presence and absence of SCF, and after 8 days of culture, we quantified cell content in each well. As shown in Figure 3B , 1,25(OH)2D3 inhibited in a dose-dependent manner bone marrow cell proliferation in response to IL-3, with or without exogenous SCF. IC50 values of 8.2 nM and 17.6 nM were obtained for inhibition of bone marrow cell culture proliferation with, respectively, IL-3 alone or IL-3 + SCF.

Dose-dependent induction of apoptosis of BMMC precursors by 1,25(OH)2D3
To determine whether antiproliferative effects of 1,25(OH)2D3 on MC precursors were dependent on induction of cell death, we cultured bone marrow-derived cells in the presence or absence of 1,25(OH)2D3 and analyzed the number of alive and dead cells accumulating during cell culture. We observed that exposure to 1,25(OH)2D3 progressively increased the number of dead cells in the culture, eventually leading to an inability to propagate the culture (data not shown). To assess whether this effect was a result of the induction of apoptosis after a 7-day exposure to 1,25(OH)2D3, we analyzed cell phenotype by staining with annexin V, which binds phosphatidylserine residues exposed on membranes of early apoptotic and dead cells and PI, which stains dead cell genomic DNA. As shown in Figure 4A , incubation with 1,25(OH)2D3 resulted in a dose-dependent induction of apoptosis of precursor cells, with a maximal proapoptotic effect of similar intensity to that observed upon IL-3 deprivation [26 ]. To evaluate the specificity of the observed apoptotic effect on MC precursors, similar experiments were carried out by culturing bone marrow-derived cells from VDR-KO mice and their control littermates. As depicted in Figure 4B , the induction of apoptosis was detectable in cell cultures derived from VDR-wild-type mice upon exposure to 1,25(OH)2D3. Conversely, no evidence of increased apoptosis was observed when VDR-deficient bone marrow cells were cultured in the same conditions, thus confirming the requirement for VDR expression for the proapoptotic effect of 1,25(OH)2D3. The differences observed in relative percentage of apoptotic cells between Figure 4A and 4B , are probably to be attributed to the different genetic background of the mouse strains used (BALB/c mice vs. Swiss mice) [19 ].


Figure 4
View larger version (60K):
[in this window]
[in a new window]

 
Figure 4. 1,25(OH)2D3 triggers apoptosis of mouse BMMC precursors. (A) Freshly isolated bone marrow cells were incubated at 37°C in IL-3-containing medium, with or without increasing concentrations of 1,25(OH)2D3. After 8 days, cells were harvested and analyzed by flow cytometry after staining with FITC-annexin V and PI to determine the percentage of apoptotic and dead cells in the cultures. (B) Bone marrow cells derived from wild-type (wt) or VDR-KO mice and cultured with or without 100 nM 1,25(OH)2D3 were analyzed after 8 days of culture. Three independent cell cultures were derived from different animals with similar results. One representative of the three cultures is shown. Cells appearing as single-positive staining for annexin V are considered early apoptotic, and those appearing as double-positive staining for annexin V and PI are considered dead cells. These experiments have been repeated more than four times with similar results.

 
To assess at which stage of MC differentiation 1,25(OH)2D3 exerted its proapoptotic effect, we monitored the process of MC differentiation in vitro by FACS analysis of c-kit and Fc{epsilon}RI cell surface expression. In the presence of IL-3, bone marrow-derived cells first acquired expression of c-kit receptor or Fc{epsilon}RI alone and subsequently became a double-positive Fc{epsilon}RI+c-kit+ (data not shown). As Fc{epsilon}RI+c-kit cells arised early and transiently in the culture, we asked if Fc{epsilon}RI+c-kit cells represented a precursor of mature Fc{epsilon}RI+c-kit+ MCs. We therefore purified Fc{epsilon}RI+c-kit (Fig. 5 , lower panels) and Fc{epsilon}RI+c-kit+ (Fig. 5 , upper panels) populations from a 10-day-old bone marrow cell culture and cultured the purified cells in IL-3-containing medium for several days to monitor their differentiation. As shown in Figure 5 , after 24 h of culture, 16% of Fc{epsilon}RI+c-kit cells had already acquired a Fc{epsilon}RI+c-kit+ mature MC phenotype, and this percentage increased to 87% in the subsequent 8 days of culture. Morphological analysis of these newly generated double-positive cells revealed that they were truly mature MCs, as defined by their characteristic granulated morphology (data not shown).


Figure 5
View larger version (27K):
[in this window]
[in a new window]

 
Figure 5. Identification of MC precursor stages in mouse BMMC cultures. Bone marrow cells cultured for 10 days in IL-3-containing medium were stained with IgE + FITC-anti-IgE and PE-anti-ckit antibodies and then sorted in the gates as shown. Sorted cells were then recultured in IL-3-containing medium and analyzed at different time-points after staining with the same antibodies. This experiment has been repeated three times.

 
We then asked if the effect of 1,25(OH)2D3 was directed to Fc{epsilon}RI+c-kit MC precursors. To answer this question, we cultured freshly isolated bone marrow cells in IL-3-containing medium in the presence or absence of 100 nM 1,25(OH)2D3 and followed their differentiation by FACS analysis for expression of Fc{epsilon}RI and c-kit cell surface markers. As shown in Figure 6 , freshly isolated bone marrow cells contained no or few double-positive Fc{epsilon}RI+c-kit+ MCs (0.1±0.0% on a total of 4x107 cells, n=6), giving rise in 5 weeks of culture in the presence of IL-3 to a population highly enriched in mature, double-positive MCs (86.0±2.8% on a total of 1.1±0.2x108 cells, n=6). Starting from the sixth day of exposure to 1,25(OH)2D3, we observed a relatively larger decrease of Fc{epsilon}RI+c-kit and Fc{epsilon}RIc-kit+ cell subpopulations among live cells compared with the double-positive population (Fig. 6A) . Similar results were obtained in several time-course experiments, and in all cases, addition of 1,25(OH)2D3 eventually led to an inability to propagate the cell culture. To ensure continuous exposure to 1,25(OH)2D3, the experimental protocol included the addition of fresh 1,25(OH)2D3 to the culture twice a week. This procedure allowed the maintenance of constantly elevated mRNA levels of the VDR activation marker Cyp24, as determined by RT-PCR analysis at different time-points (data not shown). The relative increase in the Fc{epsilon}RI+c-kit+ cell population revealed by FACS analysis was likely to reflect the lower sensitivity of mature MCs versus their precursors to a 1,25(OH)2D3 proapoptotic effect. Accordingly, parallel analysis of cell counts in the cultures revealed that the absolute number of mature MCs was not changing after Day 6, when 1,25(OH)2D3 antiproliferative effects first became apparent (Fig. 6B , solid bars).


Figure 6
View larger version (46K):
[in this window]
[in a new window]

 
Figure 6. Proapoptotic activity of 1,25(OH)2D3 targets a Fc{epsilon}RI+ precursor of MCs. (A) Bone marrow cells cultured from Day 0, with or without 100 nM 1,25(OH)2D3, were stained at different time-points with IgE + FITC-anti-IgE and PE-anti-ckit antibodies and analyzed by FACS. Upper plots are representative of cells cultured in IL-3, and the lower plots represent cells cultured in IL-3 plus 100 nM 1,25(OH)2D3. (B) The same bone marrow cell cultures were stained with Trypan blue at the indicated time-points, and live cells were counted under optical microscope. Solid bars represent the number of mature MCs, calculated by FACS analysis of c-kit/Fc{epsilon}RI staining depicted in A, and open bars represent the number of the remaining live cells. Time-course experiments have been repeated more than six times with similar results.

 
Proapoptotic effects of 1,25(OH)2D3 target IL-3R-positive MC precursors
We then asked if 1,25(OH)2D3 treatment might affect IL-3R expression. To answer this question, we stained bone marrow cells with anti-Fc{epsilon}RI, c-kit, and IL-3R{alpha} chain antibodies and analyzed expression of these markers by FACS.

As depicted in Figure 7 , bone marrow cells cultured in the presence of 1,25(OH)2D3 showed a fourfold reduction in IL-3R{alpha}+Fc{epsilon}RI+ cell frequency, as well as a twofold reduction in the frequency of the IL-3R{alpha}+c-kit+ cell population (Fig. 7A) when compared with cells cultured in the presence of vehicle (EtOH) alone (Fig. 7B) . These findings are suggestive of a marked effect of 1,25(OH)2D3 on IL-3R-expressing cells. However, this result was not a result of down-regulation of IL-3R by 1,25(OH)2D3, as no significant down-regulation of IL-3R mRNA and protein levels was detectable before 1,25(OH)2D3 could exert its proapoptotic effect (data not shown). In further support of this, 1,25(OH)2D3 did not affect IL-3R{alpha} chain levels nor induce apoptosis in the IL-3-dependent cell line BAF-3 (data not shown).


Figure 7
View larger version (27K):
[in this window]
[in a new window]

 
Figure 7. Proapoptotic activity of 1,25(OH)2D3 targets an IL-3R{alpha}+ precursor of MCs. Bone marrow cells cultured for 11 days with or without 100 nM 1,25(OH)2D3 were stained with PE-anti-IL-3R{alpha} chain and IgE + FITC-anti-IgE (A) or FITC-anti-CD117 (B) antibodies and analyzed by FACS. One selected experiment is shown, representative of several others performed with similar results. This experiment has been repeated three times with similar results.

 
Inhibition of isolated MC precursor maturation by 1,25(OH)2D3
To dissect more precisely at which stage of MCs differentiation 1,25(OH)2D3 exerts its actions, we sorted Fc{epsilon}RI+c-kit and Fc{epsilon}RIc-kit+ cell populations from a 15-day-old bone marrow cell culture and then cultured each purified population in the presence or absence of 100 nM 1,25(OH)2D3 for several days. FACS analysis revealed that although 1,25(OH)2D3 inhibited transition of Fc{epsilon}RI+c-kit cells into mature, double-positive MCs (Fig. 8A ), it was not triggering apoptosis of Fc{epsilon}RI+c-kit cells, as indicated by morphological analysis by FACS (Fig. 8B) . Reliability of SSC/FSC analysis for evaluation of cell morphology to assess cell viability qualitatively and quantitatively was confirmed by analysis of parallel cell culture stainings with annexin V/PI and FACS analysis (data not shown).


Figure 8
View larger version (34K):
[in this window]
[in a new window]

 
Figure 8. Inhibition of MC precursor maturation by 1,25(OH)2D3. Fc{epsilon}RI+-c-kit (A, B) or Fc{epsilon}RI-c-kit+ (C, D) cells were sorted from a 15-day-old BMMC culture in IL-3 after staining with IgE + FITC-anti-IgE and PE-anti-ckit antibodies. Purified cells were then recultured in IL-3-containing medium in the presence or absence of 100 nM 1,25(OH)2D3 and analyzed at different time-points after staining with the same antibodies (A, C). For the last time-point, cell morphology is reported as analysis of forward-scattering (FSC) and side-scattering (SSC) for Fc{epsilon}RI+-c-kit (B) or Fc{epsilon}RI-c-kit+ (D) cell-derived cultures. This experiment has been repeated three times with similar results.

 
It is surprising that when sorted Fc{epsilon}RIc-kit+ cells were cultured in the presence of IL-3, a transient loss of expression of c-kit receptor occurred, followed by the acquisition of Fc{epsilon}RI expression, prior to the final maturation to double-positive Fc{epsilon}RI+c-kit+ MCs. Addition of 1,25(OH)2D3 to the culture of Fc{epsilon}RIc-kit+ cells resulted in reduced percentage of Fc{epsilon}RI+c-kit+ cells (Fig. 8C) and induction of cell death, as evident by analysis of cell morphology (Fig. 8D) . It is interesting that 1,25(OH)2D3 appeared to exert its proapoptotic effect concomitantly with the acquisition of Fc{epsilon}RI expression on the cell surface (data not shown).

VDR expression is required for 1,25(OH)2D3-mediated modulation of MC precursor differentiation
To confirm the specificity of the effects of 1,25(OH)2D3 on BMMC cultures, we analyzed the phenotype of VDR-KO mice- and control littermate-derived bone marrow cells cultured in the presence of 1,25(OH)2D3. As depicted in Figure 9A , VDR-KO bone marrow cells were able to generate mature MCs, regardless the addition of 1,25(OH)2D3, whereas development of MCs from wild-type mice was inhibited by 1,25(OH)2D3.


Figure 9
View larger version (37K):
[in this window]
[in a new window]

 
Figure 9. MC development in the absence of VDR signaling in vitro. (A) Ten-day-old bone marrow cells derived from wild-type or VDR-KO mice and cultured with or without 100 nM 1,25(OH)2D3 were stained with IgE + FITC-anti-IgE and PE-anti-CD117 antibodies and analyzed by FACS. Each graph is representative of three independent cultures derived from different animals. (B) Bone marrow cells derived from wild-type or VDR-KO mice, bred on normal (N) or a calcium-supplemented (Ca) diet were cultured in IL-3-containing medium and analyzed by FACS at the indicated time-points after staining with IgE + FITC-anti-IgE and PE-anti-CD117 antibodies. This experiment has been repeated three times with similar results.

 
FACS analysis of VDR-KO and wild-type cells also allowed us to evaluate possible effects of VDR basal activity on bone marrow-derived cell cultures. As shown in Figure 9B , hematopoietic precursors derived from c-kit+-enriched VDR-deficient bone marrow cell preparations were found to undergo an accelerated maturation into MCs when compared with wild-type cells. The same effect was observed when VDR-KO mice were fed with a normal diet (Fig. 9B , center panels) and when they were fed with a calcium-supplemented diet to prevent hypocalcemia (Fig. 9B , bottom panels).

Lack of VDR expression leads to generation of more responsive MCs in vitro and to higher densities of mature MCs in the skin
Finally, we have asked if VDR basal activity might play a role in determining mature MC activity. We therefore studied activation of in vitro-differentiated MCs obtained from VDR-KO mice and control littermates. Although no difference was observed on IgE-induced degranulation between wild-type and VDR-KO MCs (data not shown), mature VDR-KO MCs were found to be more responsive than wild-type cells to Fc{epsilon}RI receptor cross-linking stimulation in terms of secretion of IL-6, IL-13, or LTC-4 (Fig. 10A ). We obtained similar results with cells obtained from animals that were fed with a normal diet or with a diet containing high levels of calcium, thus proving that the differences observed were not a result of alterations in blood calcium levels. Indeed, analysis of calcium levels in sera revealed that although lack of VDR per se resulted in the expected decrease in calcium levels, feeding these animals with a calcium-enriched diet induced a marked raise in calcium levels compared with wild-type control littermates (Fig. 10B) .


Figure 10
View larger version (18K):
[in this window]
[in a new window]

 
Figure 10. In vivo development and MC responsiveness in the absence of VDR signaling. (A) BMMCs obtained from wild-type or VDR-KO mice were stimulated by plating onto 96-well plates previously coated with purified IgE antibodies, and activation was assayed by measuring secretion of IL-6, IL-13, and LTC-4 in the culture supernatant. *, P < 0.05 vs. IgE-stimulated wild-type; ***, P < 0.004 vs. IgE-stimulated wild-type. (B) Calcium levels were evaluated in sera prepared from wild-type and VDR-KO animals upon sacrifice. *, P < 0.05, versus wild-type; **, P < 0.01, versus wild-type. (C) Skin tissue samples obtained from wild-type or VDR-KO mice were stained with toluidine blue, and mature, granulated MCs were counted. Results are reported as number of MCs/mm2 dermis. *, P < 0.05, versus wild-type.

 
We also tested if VDR signal deficiency leads to alterations in tissue MC densities in vivo. Tissue sections from wild-type and VDR-deficient animals were analyzed by histological examinations to determine the density of MCs within the tissue. Although no differences were observed while analyzing preparations from spleen, uterus, colon, bone marrow, and blood smears, the analysis of back and ear skin samples prepared from VDR-deficient mice showed a moderately higher number of mature MCs compared with wild-type control littermates (Fig. 10C) . Also, in this case, similar results were found when analyzing samples obtained from VDR-KO animals fed on a normal or calcium-enriched diet. Altogether, these results add further evidence to the hypothesis of a role of 1,25(OH)2D3 in regulation of MC development under physiological conditions.


    DISCUSSION
 TOP
 ABSTRACT
 INTRODUCTION
 MATERIALS AND METHODS
 RESULTS
 DISCUSSION
 REFERENCES
 
MCs originate in vivo from hematopoietic progenitors. Upon leaving the bone marrow, these cells circulate as undifferentiated progenitor cells until they colonize peripheral tissues, where they eventually reach their final maturation stage. In humans and rodents, mature MCs can acquire several distinct phenotypes, mainly distinguished on the basis of their protease repertoire and their tissue distribution [27 , 28 ].

MCs act as potent effectors of innate as well as adaptive immune responses, and their activity requires strict regulation. Indeed, disregulated MC activity is associated with severe inflammatory diseases such as allergy and asthma, inflammatory bowel disease, and multiple sclerosis [6 , 29 30 31 ]. A common feature of these disorders is represented by an increased number of mature MCs in the inflamed tissues. This is also observed in systemic mastocytosis, a clonal neoplasm of the MC hematopoietic progenitor associated with gain-of-function mutations involving the tyrosine kinase domain of c-kit [30 , 32 ]. Several efforts have been made in the past years to identify drug candidates able to treat these pathologies by inhibiting MC activation [33 34 35 ]. Preventing MC precursor differentiation into mature MCs may represent an alternative approach to treat MC-dependent diseases, aimed at reducing the number of responsive MCs in the tissues.

mMCs can be generated in large amounts from bone marrow cells cultured in the presence of IL-3 [12 ]. Numerous other growth factors, including IL-4, IL-9, IL-10, nerve growth factor, and SCF, have been shown to be important for MC development [36 , 37 ]. In particular, SCF, a hematopoietic cytokine that exerts its biological functions by virtue of binding to the c-kit receptor, plays, together with IL-3, a critical role in MC survival, proliferation, activation, and mediator content release [13 14 15 ]. Using IL-3-deficient mice, it has been shown that IL-3, although not essential for the generation of MC under physiological conditions, contributes to increased numbers of tissue MCs and immunity to nematode infections [38 ]. Moreover, IL-3 perfusion in W/Wv mice, which almost completely lack cutaneous MCs, restores a normal number of MCs in the skin [39 ], confirming the important role of IL-3 in MC development. It has been proposed recently that the stage of the mouse BMMC-committed progenitor (MCP) might be identified by a LynSca-1Lyc6 CD27ß7+T1/ST2+c-kit+Fc{epsilon}RI{alpha} pattern of surface expression [40 , 41 ]. According to this, transfer of this cell population into the c-kit-mutant, MC-deficient mice reconstitutes the MC compartment in vivo [41 ]. However, the identification of this MCP population does not rule out the possibility that other cell populations develop in vitro or in vivo into MCs or that different intermediate populations appear during the development process.

The findings we show here demonstrate that the Fc{epsilon}RI+c-kit stage might represent a transient MC precursor population. This observation appears to be in contrast with previous studies, suggesting that c-kit expression precedes that of Fc{epsilon}RI during in vitro MC development [42 ]. Conversely, our findings are supported by earlier evidence describing the presence of a nonbasophil, Fc{epsilon}RI+c-kit MC population in murine bone marrow cultures, which contains fewer granules than mature c-kit-expressing MCs and shows Fc{epsilon}RI expression before that of c-kit [43 ]. Also, previous studies reported the early expression of Fc{epsilon}RI in mouse bone marrow cell culture, which did not correlate with the cellular granule content [44 ], and culture of Fc{epsilon}RI+ cells sorted from a murine bone marrow cell culture on Day 3 was found to give rise to pure MC populations [45 ]. Our study shows that sorted Fc{epsilon}RI+c-kit cells cultured in the presence of IL-3 underwent a differentiation process in the presence of minimal cell proliferation into a cell population composed of 90% Fc{epsilon}RI+c-kit+ double-positive, granulated, mature MCs. Furthermore, as depicted in Figure 8C , when sorted Fc{epsilon}RIc-kit+ cells were cultured in the same way, a surprising, transient loss of expression of the c-kit receptor occurred, followed by the acquisition of Fc{epsilon}RI expression alone before final maturation into double-positive Fc{epsilon}RI+c-kit+ MCs. One possibility might be that c-kit expression could be transiently modulated in response to endogenously produced SCF or in response to other stimuli or conditions present in the culture.

The aim of this study was to investigate if and how proliferation, differentiation, and survival of MC precursors might be affected by 1,25(OH)2D3. The biological actions of 1,25(OH)2D3 go far beyond the regulation of bone metabolism and calcium homeostasis, including regulation of immunity, angiogenesis and growth, differentiation, and apoptosis of many cell types [1 2 3 ]. Most of the studies investigating activity of 1,25(OH)2D3 in regulation of inflammatory response were aimed at demonstrating that 1,25(OH)2D3 exerts inhibitory effects on Th1-type immune responses [5 , 46 , 47 ]. However, recent evidences suggested an inhibitory role of 1,25(OH)2D3 also on Th2 responses. In fact, 1,25(OH)2D3 has been shown to inhibit the Th2 cytokine IL-4 in naive T cells during their in vitro polarization [48 ], and VDR-deficient mice were found to undergo enhanced IL-4 production by CD4+ lymphocytes and enhanced T cell proliferation in response to IL-4 [49 ]. Furthermore, in a study by Wittke et al. [50 ], VDR-KO mice were shown to exhibit highly increased levels of IgE under physiological conditions. In their work, the authors showed that VDR deficiency led to an inability to develop experimental allergic asthma, thereby leading to hypothesize an important role for the 1,25(OH)2D3 endocrine system in the generation of Th2-driven inflammation in the lung [50 ]. However, in our opinion, such hypothesis is not the sole explanation of the available data. In fact, the extremely high levels of IgE antibodies circulating in VDR-KO mice might saturate MC Fc{epsilon}RI receptors, thereby preventing binding of OVA-specific IgE antibodies and MC activation, and in contrast to the suggestion made by Wittke et al. [50 ], the high levels of IgE actually indicate a suppressive effect of 1,25(OH)2D3 on the Th2 response. Therefore, those data might not really demonstrate a role for VDR in the generation of Th2-driven inflammation [51 , 52 ]. In support of a suppressive effect of 1,25(OH)2D3 on Th2 responses, Topilski et al. [53 ] have shown that 1,25(OH)2D3 has anti-inflammatory effects in a Th2-dependent asthma model in vivo, and we have recently described that BXL-628, a synthetic analog of 1,25(OH)2D3, inhibits bladder inflammation in a Th2-dependent, allergic model of interstitial cystitis [54 ]. BXL-628 effects included down-regulation of mature MC density within the bladder, as revealed by histological analysis of bladder specimens and by gene expression analysis of several MC markers (mMCP-2, mMCP-4). In this model, in vivo inhibitory activity of the 1,25(OH)2D3 analog BXL-628 was also testified by down-regulation of blood levels of the mMCP-1, which were elevated concomitantly with the onset of inflammation in positive control animals [54 ].

The data we showed in the current study provide a possible mechanism of action for 1,25(OH)2D3 in inhibiting MC activity, by means of down-regulating MC development, differentiation, and eventually function. We found that 1,25(OH)2D3 partially inhibits the release of inflammatory mediators by BMMCs stimulated by Fc{epsilon}RI cross-linking. This appears to be in contrast with previous studies documenting 1,25(OH)2D3 activity in enhancing IgE-mediated degranulation of the C57 MC line [18 ] and supporting earlier evidence of 1,25(OH)2D3 inhibiting calcium ionophore-induced histamine release by peritoneal MCs [17 ]. However, the effects on degranulation were partial and only observed at high doses of 1,25(OH)2D3 and therefore, appear to limit the possibility that VDR plays a major role in mature BMMC activation. In contrast, 1,25(OH)2D3 dose-dependently and dramatically prevents the appearance of Fc{epsilon}RI+c-kit cells by inducing apoptosis of earlier progenitor cells and inhibits further maturation of cells that have already acquired the Fc{epsilon}RI. These effects are highly specific, as they depend on expression of VDR and provide a basis for further exploring the possibility to use 1,25(OH)2D3 and its analogs in the treatment of MC-related disorders. Moreover, our data suggest that VDR activity might play a role under physiological conditions in regulating MC differentiation. VDR-deficient MC progenitors cultured in vitro show an accelerated development into mature MCs and are more responsive to Fc{epsilon}RI-mediated stimulation. It is important that VDR-deficient mice show slightly higher densities of mature MCs in the skin, possibly indicative of a higher rate of differentiation in vivo in the absence of VDR basal activity. These results are not secondary to alterations in calcium blood levels and therefore, support the hypothesis of a physiological involvement of VDR in regulation of MC development. The reported high levels of IgE antibodies circulating in VDR-KO mice [50 ] might also play a role in the maintenance of higher MC levels in the skin. In fact, binding of IgE antibodies to Fc{epsilon}RI has been shown to regulate cellular function and to promote MC survival, and monomeric IgE is capable of rendering MCs resistant to apoptosis induced by growth factor deprivation, even in the absence of Fc{epsilon}RI cross-linking [7 ]. The relative contribution of this effect to the increased number of MCs observed in the skin of VDR-deficient mice remains to be determined.

The data we show here add new evidence to several earlier studies showing that 1,25(OH)2D3 can regulate survival and differentiation of various cell lines, including malignant cells [1 , 55 , 56 ] and several immune cell types, comprising dendritic cells (DC) and macrophages [2 , 57 ]. 1,25(OH)2D3 prevents differentiation of monocytes into immature DC and inhibits maturation of DC. Differently from what we show here for MCs, 1,25(OH)2D3 exerts proapoptotic effects mainly on mature DC instead of precursor cells [2 ]. Differently, in bone marrow macrophage precursor cultures with CSF-1, 1,25(OH)2D3 exerts antiproliferative effects and induces macrophage differentiation [57 ].

Here, we have observed that 1,25(OH)2D3 can exert discrete effects on survival and differentiation of MC precursors. In particular, 1,25(OH)2D3 appears to have developmental stage-dependent effects, by inhibiting final maturation of Fc{epsilon}RI expressing late MC precursors without affecting their viability and inducing apoptosis of early MC precursors, possibly at the time of the acquisition of Fc{epsilon}RI expression. Given the fact that MCs represent a principal effector cell type of Th2 responses, our results add supporting evidence and a novel mechanism by which 1,25(OH)2D3 can inhibit allergic inflammatory responses [48 49 50 , 53 , 54 ]. Furthermore, our data support a role for VDR in MC development under physiological conditions and raise the possibility to use 1,25(OH)2D3 analogs in the treatment of MC-related disorders such as mastocytosis. Future investigations will be needed to further clarify the role played by VDR in the regulation of MC maturation and function in physiological as well as pathological settings, such as those associated with allergic responses and parasite infections.


    ACKNOWLEDGEMENTS
 
We acknowledge financial support from the VI Framework program EU Grant MAIN. We thank Dr. Francesca Sanvito for supporting the histopathological evaluations.

Received May 11, 2006; revised September 1, 2006; accepted September 7, 2006.


    REFERENCES
 TOP
 ABSTRACT
 INTRODUCTION
 MATERIALS AND METHODS
 RESULTS
 DISCUSSION
 REFERENCES
 

  1. Brown, A. J., Dusso, A., Slatopolsky, E. (1999) Vitamin D Am. J. Physiol. 277,F157-F175
  2. Penna, G., Adorini, L. (2000) 1 {alpha},25-Dihydroxyvitamin D3 inhibits differentiation, maturation, activation, and survival of dendritic cells leading to impaired alloreactive T cell activation J. Immunol. 164,2405-2411[Abstract/Free Full Text]
  3. Adorini, L., Giarratana, N., Penna, G. (2004) Pharmacological induction of tolerogenic dendritic cells and regulatory T cells Semin. Immunol. 16,127-134[CrossRef][Medline]
  4. Mathieu, C., Adorini, L. (2002) The coming of age of 1,25-dihydroxyvitamin D(3) analogs as immunomodulatory agents Trends Mol. Med. 8,174-179[CrossRef][Medline]
  5. Adorini, L. (2005) Intervention in autoimmunity: the potential of vitamin D receptor agonists Cell. Immunol. 233,115-124[CrossRef][Medline]
  6. Galli, S. J. (1997) Complexity and redundancy in the pathogenesis of asthma: reassessing the roles of mast cells and T cells J. Exp. Med. 186,343-347[Free Full Text]
  7. Kawakami, T., Galli, S. J. (2002) Regulation of mast-cell and basophil function and survival by IgE Nat. Rev. Immunol. 2,773-786[CrossRef][Medline]
  8. Brandt, E. B., Strait, R. T., Hershko, D., Wang, Q., Muntel, E. E., Scribner, T. A., Zimmermann, N., Finkelman, F. D., Rothenberg, M. E. (2003) Mast cells are required for experimental oral allergen-induced diarrhea J. Clin. Invest. 112,1666-1677[CrossRef][Medline]
  9. Theoharides, T. C., Donelan, J. M., Papadopoulou, N., Cao, J., Kempuraj, D., Conti, P. (2004) Mast cells as targets of corticotropin-releasing factor and related peptides Trends Pharmacol. Sci. 25,563-568[CrossRef][Medline]
  10. Oehlke, J., Lorenz, D., Wiesner, B., Bienert, M. (2005) Studies on the cellular uptake of substance P and lysine-rich, KLA-derived model peptides J. Mol. Recognit. 18,50-59[CrossRef][Medline]
  11. Metcalfe, D. D., Baram, D., Mekori, Y. A. (1997) Mast cells Physiol. Rev. 77,1033-1079[Abstract/Free Full Text]
  12. Levi-Schaffer, F., Shalit, M. (1989) Differential release of histamine and prostaglandin D2 in rat peritoneal mast cells activated with peptides Int. Arch. Allergy Appl. Immunol. 90,352-357[Medline]
  13. Ogasawara, T., Murakami, M., Suzuki-Nishimura, T., Uchida, M. K., Kudo, I. (1997) Mouse bone marrow-derived mast cells undergo exocytosis, prostanoid generation, and cytokine expression in response to G protein-activating polybasic compounds after coculture with fibroblasts in the presence of c-kit ligand J. Immunol. 158,393-404[Abstract]
  14. Gagari, E., Tsai, M., Lantz, C. S., Fox, L. G., Galli, S. J. (1997) Differential release of mast cell interleukin-6 via c-kit Blood 89,2654-2663[Abstract/Free Full Text]
  15. Karimi, K., Kool, M., Nijkamp, F. P., Redegeld, F. A. (2004) Substance P can stimulate prostaglandin D2 and leukotriene C4 generation without granule exocytosis in murine mast cells Eur. J. Pharmacol. 489,49-54[CrossRef][Medline]
  16. Babina, M., Krautheim, M., Grutzkau, A., Henz, B. M. (2000) Human leukemic (HMC-1) mast cells are responsive to 1{alpha}, 25-dihydroxyvitamin D(3): selective promotion of ICAM-3 expression and constitutive presence of vitamin D(3) receptor Biochem. Biophys. Res. Commun. 273,1104-1110[CrossRef][Medline]
  17. Toyota, N., Sakai, H., Takahashi, H., Hashimoto, Y., Iizuka, H. (1996) Inhibitory effect of 1 {alpha},25-dihydroxyvitamin D3 on mast cell proliferation and A23187-induced histamine release, also accompanied by a decreased c-kit receptor Arch. Dermatol. Res. 288,709-715[Medline]
  18. Shalita-Chesner, M., Koren, R., Mekori, Y. A., Baram, D., Rotem, C., Liberman, U. A., Ravid, A. (1998) 1,25-Dihydroxyvitamin D3 enhances degranulation of mast cells Mol. Cell. Endocrinol. 142,49-55[CrossRef][Medline]
  19. Van Cromphaut, S. J., Dewerchin, M., Hoenderop, J. G., Stockmans, I., Van Herck, E., Kato, S., Bindels, R. J., Collen, D., Carmeliet, P., Bouillon, R., Carmeliet, G. (2001) Duodenal calcium absorption in vitamin D receptor-knockout mice: functional and molecular aspects Proc. Natl. Acad. Sci. USA 98,13324-13329[Abstract/Free Full Text]
  20. Ortega, E., Schweitzer-Stenner, R., Pecht, I. (1988) Possible orientational constraints determine secretory signals induced by aggregation of IgE receptors on mast cells EMBO J. 7,4101-4109[Medline]
  21. Valent, P., Ashman, L. K., Hinterberger, W., Eckersberger, F., Majdic, O., Lechner, K., Bettelheim, P. (1989) Mast cell typing: demonstration of a distinct hematopoietic cell type and evidence for immunophenotypic relationship to mononuclear phagocytes Blood 73,1778-1785[Abstract/Free Full Text]
  22. Malloy, P. J., Hochberg, Z., Pike, J. W., Feldman, D. (1989) Abnormal binding of vitamin D receptors to deoxyribonucleic acid in a kindred with vitamin D-dependent rickets, type II J. Clin. Endocrinol. Metab. 68,263-269[Abstract]
  23. Ishizaka, T., Ishizaka, K. (1984) Activation of mast cells for mediator release through IgE receptors Prog. Allergy 34,188-235[Medline]
  24. Ishizaka, T., Conrad, D. H., Schulman, E. S., Sterk, A. R., Ko, C. G., Ishizaka, K. (1984) IgE-mediated triggering signals for mediator release from human mast cells and basophils Fed. Proc. 43,2840-2845[Medline]
  25. Rofolovitch, M., Amira, M., Ginsburg, H. (1987) Degranulation of in vitro differentiated mast cells stimulated by two monoclonal IgE specificities Eur. J. Immunol. 17,385-392[Medline]
  26. Mekori, Y. A., Oh, C. K., Metcalfe, D. D. (1993) IL-3-dependent murine mast cells undergo apoptosis on removal of IL-3. Prevention of apoptosis by c-kit ligand J. Immunol. 151,3775-3784[Abstract]
  27. Kambe, N., Hiramatsu, H., Shimonaka, M., Fujino, H., Nishikomori, R., Heike, T., Ito, M., Kobayashi, K., Ueyama, Y., Matsuyoshi, N., Miyachi, Y., Nakahata, T. (2004) Development of both human connective tissue-type and mucosal-type mast cells in mice from hematopoietic stem cells with identical distribution pattern to human body Blood 103,860-867[Abstract/Free Full Text]
  28. Galli, S. J., Wershil, B. K. (1996) The two faces of the mast cell Nature 381,21-22[CrossRef][Medline]
  29. Galli, S. J. (1993) New concepts about the mast cell N. Engl. J. Med. 328,257-265[Free Full Text]
  30. Metcalfe, D. D., Akin, C. (2001) Mastocytosis: molecular mechanisms and clinical disease heterogeneity Leuk. Res. 25,577-582[CrossRef][Medline]
  31. Xie, H., He, S. H. (2005) Roles of histamine and its receptors in allergic and inflammatory bowel diseases World J. Gastroenterol. 11,2851-2857[Medline]
  32. Valent, P., Akin, C., Sperr, W. R., Mayerhofer, M., Fodinger, M., Fritsche-Polanz, R., Sotlar, K., Escribano, L., Arock, M., Horny, H. P., Metcalfe, D. D. (2005) Mastocytosis: pathology, genetics, and current options for therapy Leuk. Lymphoma 46,35-48[CrossRef][Medline]
  33. Reber, L., Da Silva, C. A., Frossard, N. (2006) Stem cell factor and its receptor c-Kit as targets for inflammatory diseases Eur. J. Pharmacol. 533,327-340[CrossRef][Medline]
  34. Puxeddu, I., Ribatti, D., Crivellato, E., Levi-Schaffer, F. (2005) Mast cells and eosinophils: a novel link between inflammation and angiogenesis in allergic diseases J. Allergy Clin. Immunol. 116,531-536[CrossRef][Medline]
  35. Chang, T. W., Shiung, Y. Y. (2006) Anti-IgE as a mast cell-stabilizing therapeutic agent J. Allergy Clin. Immunol. 117,1203-1212[CrossRef][Medline]
  36. Lantz, C. S., Huff, T. F. (1995) Differential responsiveness of purified mouse c-kit+ mast cells and their progenitors to IL-3 and stem cell factor J. Immunol. 155,4024-4029[Abstract]
  37. Tsuji, K., Zsebo, K. M., Ogawa, M. (1991) Murine mast cell colony formation supported by IL-3, IL-4, and recombinant rat stem cell factor, ligand for c-kit J. Cell. Physiol. 148,362-369[CrossRef][Medline]
  38. Lantz, C. S., Boesiger, J., Song, C. H., Mach, N., Kobayashi, T., Mulligan, R. C., Nawa, Y., Dranoff, G., Galli, S. J. (1998) Role for interleukin-3 in mast-cell and basophil development and in immunity to parasites Nature 392,90-93[CrossRef][Medline]
  39. Ody, C., Kindler, V., Vassalli, P. (1990) Interleukin 3 perfusion in W/Wv mice allows the development of macroscopic hematopoietic spleen colonies and restores cutaneous mast cell number J. Exp. Med. 172,403-406[Abstract/Free Full Text]
  40. Rodewald, H. R., Dessing, M., Dvorak, A. M., Galli, S. J. (1996) Identification of a committed precursor for the mast cell lineage Science 271,818-822[Abstract]
  41. Chen, C. C., Grimbaldeston, M. A., Tsai, M., Weissman, I. L., Galli, S. J. (2005) Identification of mast cell progenitors in adult mice Proc. Natl. Acad. Sci. USA 102,11408-11413[Abstract/Free Full Text]
  42. Lantz, C. S., Huff, T. F. (1995) Murine kit+ lineage-bone marrow progenitors express Fc {gamma}-RII but do not express Fc {epsilon}-RI until mast cell granule formation J. Immunol. 154,355-362[Abstract]
  43. Dvorak, A. M., Seder, R. A., Paul, W. E., Morgan, E. S., Galli, S. J. (1994) Effects of interleukin-3 with or without the c-kit ligand, stem cell factor, on the survival and cytoplasmic granule formation of mouse basophils and mast cells in vitro Am. J. Pathol. 144,160-170[Abstract]
  44. Thompson, H. L., Metcalfe, D. D., Kinet, J. P. (1990) Early expression of high-affinity receptor for immunoglobulin E (Fc {epsilon} RI) during differentiation of mouse mast cells and human basophils J. Clin. Invest. 85,1227-1233[Medline]
  45. Rottem, M., Barbieri, S., Kinet, J. P., Metcalfe, D. D. (1992) Kinetics of the appearance of Fc {epsilon} RI-bearing cells in interleukin-3-dependent mouse bone marrow cultures: correlation with histamine content and mast cell maturation Blood 79,972-980[Abstract/Free Full Text]
  46. Boonstra, A., Barrat, F. J., Crain, C., Heath, V. L., Savelkoul, H. F., O’Garra, A. (2001) 1{alpha},25-Dihydroxyvitamin d3 has a direct effect on naive CD4(+) T cells to enhance the development of Th2 cells J. Immunol. 167,4974-4980[Abstract/Free Full Text]
  47. Lemire, J. M., Archer, D. C., Beck, L., Spiegelberg, H. L. (1995) Immunosuppressive actions of 1,25-dihydroxyvitamin D3: preferential inhibition of Th1 functions J. Nutr. 125,1704S-1708S[Abstract/Free Full Text]
  48. Staeva-Vieira, T. P., Freedman, L. P. (2002) 1,25-Dihydroxyvitamin D3 inhibits IFN-{gamma} and IL-4 levels during in vitro polarization of primary murine CD4+ T cells J. Immunol. 168,1181-1189[Abstract/Free Full Text]
  49. O’Kelly, J., Hisatake, J., Hisatake, Y., Bishop, J., Norman, A., Koeffler, H. P. (2002) Normal myelopoiesis but abnormal T lymphocyte responses in vitamin D receptor knockout mice J. Clin. Invest. 109,1091-1099[CrossRef][Medline]
  50. Wittke, A., Weaver, V., Mahon, B. D., August, A., Cantorna, M. T. (2004) Vitamin D receptor-deficient mice fail to develop experimental allergic asthma J. Immunol. 173,3432-3436[Abstract/Free Full Text]
  51. D’Ambrosio, D. (2005) Increased IgE but reduced Th2-type inflammation in vitamin D receptor-deficient mice J. Immunol. 174,4451[Free Full Text]
  52. Xystrakis, E., Boswell, S. E., Hawrylowicz, C. M. (2006) T regulatory cells and the control of allergic disease Expert Opin. Biol. Ther. 6,121-133[CrossRef][Medline]
  53. Topilski, I., Flaishon, L., Naveh, Y., Harmelin, A., Levo, Y., Shachar, I. (2004) The anti-inflammatory effects of 1,25-dihydroxyvitamin D3 on Th2 cells in vivo are due in part to the control of integrin-mediated T lymphocyte homing Eur. J. Immunol. 34,1068-1076[CrossRef][Medline]
  54. Benigni, F., Baroni, E., Zecevic, M., Zvara, P., Streng, T., Hedlund, P., Colli, E., D’Ambrosio, D., Andersson, K. E. (2006) Oral treatment with a vitamin D3 analogue (BXL628) has anti-inflammatory effects in rodent model of interstitial cystitis BJU Int. 97,617-624[CrossRef][Medline]
  55. Guyton, K. Z., Kensler, T. W., Posner, G. H. (2003) Vitamin D and vitamin D analogs as cancer chemopreventive agents Nutr. Rev. 61,227-238[CrossRef][Medline]
  56. Johnson, C. S., Hershberger, P. A., Bernardi, R. J., McGuire, T. F., Trump, D. L. (2002) Vitamin D receptor: a potential target for intervention Urology 60,123-130[CrossRef]